ANIMAL MODELS OF METHAMPHETAMINE-INDUCED COGNITIVE IMPAIRMENT RELEASE DATE: February 24, 2004 RFP AVAILABLE: N01DA-4-8849 NOTICE: NOT-DA-04-023 National Institute on Drug Abuse (NIDA) The National Institute on Drug Abuse (NIDA) plans to solicit proposals from qualified organizations having in-house capability to perform in vivo rodent behavioral pharmacology studies of potential pharmacotherapies for the cognitive impairment seen in methamphetamine dependence. In brief, the objectives of this project are: (1) To establish and validate animal model(s) of the cognitive impairment experienced by methamphetamine use; (2) To evaluate compounds for their potential ability to treat methamphetamine-induced cognitive deficits; (3) To evaluate compounds for their potential to exacerbate methamphetamine-induced cognitive deficits; and, (4) To evaluate the potential of compounds to produce methamphetamine-like effects on cognition. The offerors must propose the models to be developed and utilized for compound testing. The identity of proprietary test compounds will be blinded, and the resulting data will be utilized by the NIDA Medications Development Program. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. All offerors must comply with NIH guidelines on the care and use of laboratory animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf). We anticipate the award of one cost reimbursement contract for a base period of three years. The contract will include two 1-year options as well as additional quantity options. RFP No. N01DA-4-8849 will be available electronically on or about March 9, 2004. You will access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). Please note that NIDA uses a streamlined RFP format which includes only the Work Statement, Deliverables, Reporting Requirements, Special Requirements, Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. All information required for the submission of a proposal is contained in or accessible through the streamlined RFP package. Response to the RFP will be due on or about May 17, 2004. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract. Point of Contact: Kenneth E. Goodling, Contracting Officer National Institute on Drug Abuse, NIH Contracts Management Branch, OPRM 6101 Executive Blvd., Room 260, MSC 8402 Bethesda, Maryland 20892-8402 E-mail: kg25d@nih.gov Telephone: (301) 443-6677 Fax: (301) 443-7595
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |